Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Oct 15;10(10):e038294.
doi: 10.1136/bmjopen-2020-038294.

Study protocol for the PURSUIT-HFpEF study: a Prospective, Multicenter, Observational Study of Patients with Heart Failure with Preserved Ejection Fraction

Collaborators, Affiliations
Observational Study

Study protocol for the PURSUIT-HFpEF study: a Prospective, Multicenter, Observational Study of Patients with Heart Failure with Preserved Ejection Fraction

Shinichiro Suna et al. BMJ Open. .

Abstract

Introduction: Neither the pathophysiology nor an effective treatment for heart failure with preserved ejection fraction (HFpEF) has been elucidated to date. The purpose of this ongoing study is to elucidate the pathophysiology and prognostic factors for patients with HFpEF admitted to participating institutes. We also aim to obtain insights into the development of new diagnostic and treatment methods by analysing patient background factors, clinical data and follow-up information.

Methods and analysis: This study is a prospective, multicentre, observational study of patients aged ≥20 years admitted due to acute decompensated heart failure with preserved left ventricular ejection fraction (≥50%) and elevated N-terminal-pro brain natriuretic peptide (NT-proBNP) (≥400 pg/mL). The study began in June 2016, with the participation of Osaka University Hospital and 31 affiliated facilities. We will collect data on history in detail, accompanying diseases, quality of life, frailty score, medication history, and laboratory and echocardiographic data. We will follow-up each patient for 5 years, and collect outcome data on mortality, cause of death, and the number and cause of hospitalisation. The _target number of registered cases is 1500 cases in 5 years.

Ethics and dissemination: The protocol was approved by the Institutional Review Board (IRB) of Osaka University Hospital on 24 February 2016 (ID: 15471), and by the IRBs of the all participating facilities. The findings will be disseminated through peer-reviewed publications and conference presentations.

Keywords: cardiac epidemiology; cardiology; heart failure.

PubMed Disclaimer

Conflict of interest statement

Competing interests: SS has received personal fees from Nihon Medi-Physics and FUJIFILM Toyama Chemical. SH has received personal fees from Daiichi Sankyo Company, Bayer, Astellas Pharma, Pfizer Pharmaceuticals and Boehringer Ingelheim Japan, and grants from Roche Diagnostics, FUJIFILM Toyama Chemical and Actelion Pharmaceuticals. AN has received personal fees from AstraZeneca and Otsuka Pharmaceutical. YM has a leadership position and stock of MKS, and has received a grant from MKS. HM has received personal fees from Daiichi Sankyo Company, Kowa Company, Bayer and Pfizer Pharmaceuticals, and a grant from Terumo. DN has received a personal fee from Daiichi Sankyo Company. YS has received personal fees from Otsuka Pharmaceutical, Ono Pharmaceutical, Daiichi Sankyo Company, Mitsubishi Tanabe Pharma Corporation and Actelion Pharmaceuticals, and grants from Roche Diagnostic, FUJIFILM Toyama Chemical, Abbott Medical Japan, Otsuka Pharmaceutical, Daiichi Sankyo Company, Mitsubishi Tanabe Pharma Corporation and Biotronik.

Figures

Figure 1
Figure 1
Overview of the Prospective, Multicenter, Observational Study on the Prognosis of Heart Failure with Preserved Ejection Fraction study. BNP, brain natriuretic peptide; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal-pro BNP.

Similar articles

Cited by

References

    1. Roger VL. Epidemiology of heart failure. Circ Res 2013;113:646–59. 10.1161/CIRCRESAHA.113.300268 - DOI - PMC - PubMed
    1. Hernandez AF, Hammill BG, O'Connor CM, et al. . Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (organized program to initiate lifesaving treatment in hospitalized patients with heart failure) registry. J Am Coll Cardiol 2009;53:184–92. 10.1016/j.jacc.2008.09.031 - DOI - PMC - PubMed
    1. Massie BM, Carson PE, McMurray JJ, et al. . Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456–67. 10.1056/NEJMoa0805450 - DOI - PubMed
    1. Pitt B, Pfeffer MA, Assmann SF, et al. . Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383–92. 10.1056/NEJMoa1313731 - DOI - PubMed
    1. Solomon SD, McMurray JJV, Anand IS, et al. . Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609–20. 10.1056/NEJMoa1908655 - DOI - PubMed

Publication types

  NODES
Project 1
twitter 2